ALASKA NATIVE TRIBAL HEALTH CONSORTIUM

Nirsevimab Shows High Efficacy in Preventing RSV Hospitalizations in Infants

6 months ago

• A new study reveals that nirsevimab, a monoclonal antibody injection, is highly effective in preventing RSV-related hospitalizations in infants, with a 93% reduction reported. • Real-world data from Ireland demonstrates a 94% decrease in RSV hospitalizations among babies under one year old following the rollout of nirsevimab. • The CDC reports that nirsevimab reduced RSV-related hospitalizations by 89% in Alaska's Yukon-Kuskokwim Delta during the first season of its administration. • Unlike vaccines, nirsevimab provides immediate protection by directly dosing infants with antibodies, offering a crucial preventative measure against severe RSV infections.